DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
HRYZ Biotech Co.
Pfizer
Novartis
Novartis
Novartis
Pfizer
Novartis
Immodulon Therapeutics Ltd
Novartis
Novartis
Novartis
Novartis
Qilu Pharmaceutical Co., Ltd.
Novartis
SecuraBio
Novartis
Novartis
Gossamer Bio Inc.
Novartis
Novartis
Novartis
Bristol-Myers Squibb